No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group

Br J Cancer. 1997;76(8):992-1000. doi: 10.1038/bjc.1997.498.

Abstract

There is evidence that predisposition to cancer has a genetic component. Genetic models have suggested that there is at least one highly penetrant gene predisposing to this disease. The oncogene MXI1 on chromosome band 10q24-25 is mutated in a proportion of prostate tumours and loss of heterozygosity occurs at this site, suggesting the location of a tumour suppressor in this region. To investigate the possibility that MXI1 may be involved in inherited susceptibility to prostate cancer, we have sequenced the HLH and ZIP regions of the gene in 38 families with either three cases of prostate cancer or two affected siblings both diagnosed below the age of 67 years. These are the areas within which mutations have been described in some sporadic prostate cancers. No mutations were found in these two important coding regions and we therefore conclude that MXI1 does not make a major contribution to prostate cancer susceptibility.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Cluster Analysis
  • DNA, Neoplasm / genetics
  • DNA, Neoplasm / metabolism
  • Dimerization
  • Disease Susceptibility
  • GTP-Binding Proteins*
  • Germ-Line Mutation*
  • Humans
  • Male
  • Middle Aged
  • Myxovirus Resistance Proteins
  • Pedigree
  • Prostatic Neoplasms / genetics*
  • Proteins / genetics*
  • Risk Factors

Substances

  • DNA, Neoplasm
  • Myxovirus Resistance Proteins
  • Proteins
  • GTP-Binding Proteins